WO2002009702A8 - Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure - Google Patents

Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure

Info

Publication number
WO2002009702A8
WO2002009702A8 PCT/US2001/024220 US0124220W WO0209702A8 WO 2002009702 A8 WO2002009702 A8 WO 2002009702A8 US 0124220 W US0124220 W US 0124220W WO 0209702 A8 WO0209702 A8 WO 0209702A8
Authority
WO
WIPO (PCT)
Prior art keywords
indole derivatives
intraocular pressure
reducing
medicament
manufacture
Prior art date
Application number
PCT/US2001/024220
Other languages
French (fr)
Other versions
WO2002009702A2 (en
WO2002009702A3 (en
Inventor
Jesus J Pintor
Maria A Peral
Ward M Peterson
Robert Plourde Jr
Edward G Brown
Benjamin R Yerxa
Original Assignee
Inspire Pharmaceuticals Inc
Jesus J Pintor
Maria A Peral
Ward M Peterson
Robert Plourde Jr
Edward G Brown
Benjamin R Yerxa
Univ Madrid Complutense
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ES200001916A external-priority patent/ES2172415B2/en
Application filed by Inspire Pharmaceuticals Inc, Jesus J Pintor, Maria A Peral, Ward M Peterson, Robert Plourde Jr, Edward G Brown, Benjamin R Yerxa, Univ Madrid Complutense filed Critical Inspire Pharmaceuticals Inc
Priority to AU2001280984A priority Critical patent/AU2001280984A1/en
Priority to KR10-2003-7001250A priority patent/KR20030046395A/en
Priority to JP2002515255A priority patent/JP2004518612A/en
Priority to CA002417489A priority patent/CA2417489A1/en
Priority to EP01959427A priority patent/EP1307191A2/en
Priority to MXPA03000729A priority patent/MXPA03000729A/en
Publication of WO2002009702A2 publication Critical patent/WO2002009702A2/en
Publication of WO2002009702A3 publication Critical patent/WO2002009702A3/en
Publication of WO2002009702A8 publication Critical patent/WO2002009702A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention provides a method of reducing intraocular pressure by administering pharmaceutical compositions comprising indole derivatives. The pharmaceutical compositions useful in this invention comprise indole derivatives and melatonin analogs of Formulae (I) (II) (III) (IV). A preferred embodiment is a method of lowering intraocular pressure using 5-(methoxycarbonylamino)-N-acetyltryptamine (5-MCA-NAT), also known as GR 135531, which has a prolonged duration of action and greater efficacy in lowering intraocular pressure compared to melatonin. The present invention further provides a method of treating disorders associated with ocular hypertension, and a method of treating various forms of glaucoma; the method comprises administering an effective dose of a pharmaceutical composition comprising an indole derivative with or without agents commonly used to treat such disorders.
PCT/US2001/024220 2000-07-28 2001-07-27 Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure WO2002009702A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2001280984A AU2001280984A1 (en) 2000-07-28 2001-07-27 Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure
KR10-2003-7001250A KR20030046395A (en) 2000-07-28 2001-07-27 Method for reducing intraocular pressure using indole derivatives
JP2002515255A JP2004518612A (en) 2000-07-28 2001-07-27 Method for lowering intraocular pressure using indole derivatives
CA002417489A CA2417489A1 (en) 2000-07-28 2001-07-27 Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure
EP01959427A EP1307191A2 (en) 2000-07-28 2001-07-27 Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure
MXPA03000729A MXPA03000729A (en) 2000-07-28 2001-07-27 Method for reducing intraocular pressure using indole derivatives.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ES200001916A ES2172415B2 (en) 2000-07-28 2000-07-28 TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION THROUGH A MELATONINE ANALOG.
ES200001916 2000-07-28
US27688501P 2001-03-16 2001-03-16
US60/276,885 2001-03-16

Publications (3)

Publication Number Publication Date
WO2002009702A2 WO2002009702A2 (en) 2002-02-07
WO2002009702A3 WO2002009702A3 (en) 2002-12-27
WO2002009702A8 true WO2002009702A8 (en) 2003-05-08

Family

ID=26156193

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/024220 WO2002009702A2 (en) 2000-07-28 2001-07-27 Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure

Country Status (9)

Country Link
EP (1) EP1307191A2 (en)
JP (1) JP2004518612A (en)
KR (1) KR20030046395A (en)
CN (1) CN1450896A (en)
AR (1) AR035651A1 (en)
AU (1) AU2001280984A1 (en)
CA (1) CA2417489A1 (en)
MX (1) MXPA03000729A (en)
WO (1) WO2002009702A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7084128B2 (en) 2002-01-18 2006-08-01 Inspire Pharmaceuticals, Inc. Method for reducing intraocular pressure
RS51097B (en) 2002-03-26 2010-10-31 Boehringer Ingelheim Pharmaceuticals Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions,and uses thereof
CN101327325A (en) 2002-07-30 2008-12-24 奥默罗斯公司 Ophthalmologic irrigation solutions and method
ATE473740T1 (en) * 2002-08-29 2010-07-15 Boehringer Ingelheim Pharma 3-(SULFONAMIDOETHYL)-INDOLE DERIVATIVES FOR USE AS GLUCOCORTICOID MIMETICS IN THE TREATMENT OF INFLAMMATORY, ALLERGIC AND PROLIFERATIVE DISEASES
UY28526A1 (en) 2003-09-24 2005-04-29 Boehringer Ingelheim Pharma GLUCOCORTICOID MIMETICS, METHODS OF PREPARATION PHARMACEUTICAL COMPOSITIONS AND USES OF THE SAME
US7795272B2 (en) 2004-03-13 2010-09-14 Boehringer Ingelheim Pharmaceutical, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
EP1750740A4 (en) 2004-05-06 2009-06-10 Molichem Medicines Inc Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions
WO2005115432A2 (en) 2004-05-06 2005-12-08 Molichem Medicines, Inc. Treatment of ocular diseases and disorders using lantibiotic compositions
PE20060776A1 (en) 2004-12-27 2006-09-26 Boehringer Ingelheim Pharma MIMETICS OF GLUCOCORTICOIDES, METHODS TO PREPARE THEM AND PHARMACEUTICAL COMPOSITIONS
KR20090097908A (en) 2006-12-06 2009-09-16 베링거 인겔하임 인터내셔날 게엠베하 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
BRPI0816130A2 (en) 2007-08-28 2015-02-24 Baxter Int METHODS FOR MAKING A PREPARATION AND INCREASING RESISTANCE TO A VIRAL INFECTION IN AN INDIVIDUAL.
CN102112476A (en) 2008-06-06 2011-06-29 贝林格尔.英格海姆国际有限公司 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
CN104367580A (en) * 2009-11-23 2015-02-25 阿勒根公司 7-[3,5-dihydroxy-2-(3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-n-ethyl-hept-5-enamide (bimatoprost) in crystalline form ii, methods for preparation, and methods for use thereof
EA025415B1 (en) 2010-01-11 2016-12-30 Инотек Фармасьютикалз Корпорейшн Combination, kit and method of reducing intraocular pressure
JP2013523739A (en) 2010-03-26 2013-06-17 イノテック ファーマシューティカルズ コーポレイション Method for reducing intraocular pressure in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs thereof
SG10201701343QA (en) 2012-01-26 2017-04-27 Inotek Pharmaceuticals Corp Anhydrous Polymorphs of (2r,3s,4r,5r)-5-(6-(Cyclopentylamino)-9h-Purin-9-Yl)-3,4-Dihydroxytetrahydrofuran-2-Yl) } Methyl Nitrate and Processes of Preparation Thereof
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Surgical (Ireland) Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
AU2014239222A1 (en) 2013-03-15 2015-10-01 Inotek Pharmaceuticals Corporation Ophthalmic formulations
TWI809304B (en) 2014-12-01 2023-07-21 奥默羅斯公司 Anti-inflammatory and mydriatic intracameral solutions for inhibition of postoperative ocular inflammatory conditions
EP4364798A3 (en) 2018-10-05 2024-06-19 Annapurna Bio Inc. Compounds and compositions for treating conditions associated with apj receptor activity
KR20230061473A (en) * 2020-09-02 2023-05-08 인베릭 바이오사이언시스 캐나다 인크. Nitrated psilocybin derivatives and their use for modulating the 5-HT2A receptor and treating psychiatric disorders
WO2023044556A1 (en) 2021-09-24 2023-03-30 Enveric Biosciences Canada Inc. Aminated psilocybin derivatives and methods of using
AU2022380979A1 (en) 2021-11-02 2024-06-06 Flare Therapeutics Inc. Pparg inverse agonists and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4654361A (en) * 1986-01-27 1987-03-31 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Method of lowering intraocular pressure using melatonin
AU616907B2 (en) * 1987-08-17 1991-11-14 Whitby Research, Inc. Melatonin analogues
GB9420529D0 (en) * 1994-10-12 1994-11-30 Pfizer Ltd Indoles
FR2737725B1 (en) * 1995-08-08 1997-10-31 Valentonine NOVEL ACYLATED DERIVATIVES OF MELATONIN AND MELATONINERGIC ANALOGS, THEIR PREPARATION PROCESS AND THEIR USE AS MEDICAMENTS

Also Published As

Publication number Publication date
JP2004518612A (en) 2004-06-24
KR20030046395A (en) 2003-06-12
CA2417489A1 (en) 2002-02-07
WO2002009702A2 (en) 2002-02-07
MXPA03000729A (en) 2004-11-01
AR035651A1 (en) 2004-06-23
AU2001280984A1 (en) 2002-02-13
EP1307191A2 (en) 2003-05-07
CN1450896A (en) 2003-10-22
WO2002009702A3 (en) 2002-12-27

Similar Documents

Publication Publication Date Title
WO2002009702A3 (en) Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure
ES2172415A1 (en) Method for reducing intraocular pressure using indole derivatives
US5849761A (en) Peripherally active anti-hyperalgesic opiates
WO2003072066A3 (en) Compositions and methods for the treatment of glaucoma and ocular hypertension
CA2502437A1 (en) Method and composition containing latanoprost for treating ocular hypertension and glaucoma
WO2006071548A3 (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
WO2001001973A3 (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
WO2002041883A3 (en) As-needed administration of tricyclic and other non-sri antidepressant drugs to treat premature ejaculation
TW200733964A (en) (Indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines for treating rho kinase-mediated diseases and conditions
WO2001092282A3 (en) Methods and compositions for treating flaviviruses and pestiviruses
ES2295609T3 (en) TIADIAZOLILPIPERAZINA DERIVATIVES USEFUL TO TREAT OR PREVENT A PAIN.
TWI367751B (en) Pharmaceutical composition comprising rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
CA2454976A1 (en) Therapeutic agent for glaucoma comprising compound having pi3 kinase inhibitory action as active ingredient
WO2005115432A3 (en) Treatment of ocular diseases and disorders using lantibiotic compositions
WO2002044174A3 (en) 3-(2,4-dimethylthiazol-5-yl) indeno[1,2-c]pyrazol-4-one derivatives as cdk inhibitors
EP1110554A4 (en) Medicinal compositions for treating eye diseases
ATE359794T1 (en) 3, 7 THIAPROSTANIC ACID DERIVATIVES AS AN AGENT FOR REDUCING INTERNAL EYE PRESSURE
AR009028A1 (en) PHARMACEUTICAL COMPOSITIONS, A PROCEDURE FOR PREPARING SUCH COMPOSITIONS AND USE OF SUCH COMPOSITIONS IN THE TREATMENT OF OPHTHALMIC DISEASES AND METHODS FOR TREATING SUCH DISEASES
CA2505086A1 (en) Ophthalmic compositions for treating ocular hypertension
BR0314419A (en) Substituted 5-chroman-5-yl-ethylamine compounds, their use and pharmaceutical composition including
WO1995034302A3 (en) Method for reducing intraocular pressure in the mammalian eye by administration of calcium chelators
AU2001267864A1 (en) Remedial agent for optic nerve disease and the like
ATE352317T1 (en) THERAPEUTIC TREATMENT OF EOSINOPHILY BY USING CHYMASE INHIBITORS AS ACTIVE INGREDIENTS
BR0209601A (en) Method for the treatment of ocular hypertension and glaucoma

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2001280984

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/000729

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2417489

Country of ref document: CA

Ref document number: 1020037001250

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2001959427

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 018150969

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2001959427

Country of ref document: EP

WSNC Later publication of a supplementary international search report together with a suppl. search report established by non-competent authority
WWP Wipo information: published in national office

Ref document number: 1020037001250

Country of ref document: KR

ENPW Started to enter national phase and was withdrawn or failed for other reasons

Ref document number: PI0112817

Country of ref document: BR

Free format text: PEDIDO RETIRADO FACE A IMPOSSIBILIDADE DE ACEITACAO DA ENTRADA NA FASE NACIONAL POR TER SIDO INTEMPESTIVA. O PRAZO LIMITE PARA ENTRADA NA FASE NACIONAL EXPIRAVA EM 28.03.2002(20 MESES - BR DESIGNADO APENAS) , E A PRETENSA ENTRADA NA FASE NACIONAL SO OCORREU EM 28.01.2003.

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)